Third cohort completed in Aptahem’s FIH study
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the third cohort of healthy volunteers (HV) has been dosed and completed in the clinical First in Human (FIH) study.After the follow-up visits of this third cohort, Apta-1 continues to be safe and well tolerated. The study will continue according to plan with dosing HV in the fourth cohort later this month. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem